MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study - Nantes Université
Article Dans Une Revue Clinical Lymphoma, Myeloma & Leukemia Année : 2022

MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study

Fichier non déposé

Dates et versions

hal-04757091 , version 1 (28-10-2024)

Identifiants

Citer

Jonathon Cohen, Nirav Shah, Alvaro Alencar, James Gerson, Manish Patel, et al.. MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study. Clinical Lymphoma, Myeloma & Leukemia, 2022, 22, pp.S394-S395. ⟨10.1016/S2152-2650(22)01569-5⟩. ⟨hal-04757091⟩
0 Consultations
0 Téléchargements

Altmetric

Partager

More